# GALAXIES Lung-301 (NCT06472076)

> A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: belrestotug plus dostarlimab
- Indication: previously untreated PD-L1 high non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06472076
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Lung Cancer, Non-Small Cell
- Interventions: Dostarlimab; Belrestotug; Pembrolizumab; Placebo
- Enrollment: 88
- Primary outcome: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
- Primary outcome: Number of Participants with TEAEs or SAEs leading to dose withdrawals or treatment discontinuation

## Indexed commentary on GALAXIES Lung-301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=galaxies-lung-301-nct06472076
